Pharma & Biotech

A significant regulatory warning from the U.S. Food and Drug Administration (FDA) has triggered a sharp sell-off in ImmunityBio shares....

A surge in institutional buying activity is placing a traditional healthcare conglomerate firmly on the radar of major market players....

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical company faces a...

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational improvements but also...

As Humacyte prepares to release its full-year 2025 financial results, the biotechnology firm finds its stock trading at a historic...

Despite reporting operational headway and a narrower-than-expected quarterly loss, Talphera's stock experienced significant selling pressure. The market's focus appears fixed...

Lexaria Bioscience is positioning its proprietary DehydraTECH technology as a potential solution to a critical problem plaguing popular weight-loss and...

In a surprising market reaction, shares of biotechnology firm Ocugen experienced a significant sell-off this week, even as the company...

Hikma Pharmaceuticals has been demoted from the UK's premier stock market index. Effective from the start of trading on Monday,...

Nvidia is broadening its horizons. The chipmaker's latest collaborations with major utility and pharmaceutical firms signal a deliberate push to...